The Globe and Mail reports in its Wednesday, Aug. 14, edition that Stifel analyst Justin Keywood expects continued market volatility in the North American pharmaceuticals sector, pointing to "macro uncertainty as the U.S. election approaches." The Globe's David Leeder writes in the Eye On Equities column that Mr. Keywood has elevated his recommendation for Medexus Pharmaceuticals to "buy" from "speculative buy." Mr. Keywood gave his share target a 20-cent boost to $3. Analysts on average target the shares at $3.18. Mr. Keywood says in a note: "Medexus is a cross-border specialty pharma company but with bio-tech like characteristics. The base business is profitable and cash flow positive, but the focus remains on a potential FDA-approval for Orphan-drug status, Treosulfan that could double sales and lead to material profit inflection. The FDA is expected to issue a decision on Treosulfan by late October, 2024, serving as a potential near-term catalyst. The FDA review marks a third submission after a complete response letter in 2021 and second incomplete response in 2022. We were encouraged to see the FDA accept Treosulfan for review in April, 2024, and in our view, suggests that the data package is now in order."